生物制剂治疗所致乙型肝炎病毒再激活研究进展  

Hepatitis B virus reactivation during biologics therapy

作　　者：李杨洲(综述)[1] 陆爽(审校) Li Yangzhou;Lu Shuang(Department of Infectious Diseases,Affiliated Hospital,Guizhou Medical University,Guiyang 550001,Guizhou Province,China)

机构地区：[1]贵州医科大学,贵阳市550001 [2]贵州医科大学附属医院感染病科,贵阳市550001

出　　处：《实用肝脏病杂志》2023年第2期297-300,共4页Journal of Practical Hepatology

摘　　要：目的 随着生物制剂在临床逐步广泛的应用,由此导致的乙型肝炎病毒(HBV)再激活越来越受关注。HBV再激活的患者可发生肝衰竭,甚至导致死亡。对有HBV再激活发生风险的人群进行筛查、预防性抗病毒治疗和监测,已经成为各大指南的共识。本文就在应用生物制剂治疗过程中HBV再激活的发生风险分层、发生机制和预防性抗病毒治疗药物应用等作一综述。Objective With the wide application of biologics, the hepatitis B virus(HBV) reactivation have been increasingly become a problem. The patients with HBV reactivation may suffer from liver failure, which might lead to death. The screening, prophylactic antiviral therapy and surveillance for the patients at a risk of HBV reactivation have become the consensus of major related guidelines. In this article, we reviewed the population risk stratification, mechanism by which the HBV reactivated, and the prophylactic antiviral agents.

关 键 词：乙型肝炎病毒 生物制剂 再激活 

分 类 号：R512.62[医药卫生—内科学]